Part-Time

Clinical Support Specialist

MedRhythms

MedRhythms

51-200 employees

Neurotherapeutics platform combining sensors, software, music

No salary listed

Portland, ME, USA

Hybrid

Category
Customer Experience & Support (1)
Required Skills
Zendesk
Salesforce

Get referred to MedRhythms

See people who can refer or advise you

Requirements
  • Strong communication and interpersonal skills are required to engage effectively and build relationships with patients and caregivers.
  • Strong problem-solving abilities and a proactive, solution-oriented mindset are required.
  • The ability to adapt quickly to evolving patient and caregiver needs, using judgment and initiative, is required.
  • Technical aptitude and the ability to quickly learn and understand complex software platforms are required.
  • Interest in healthcare, digital therapeutics, or life sciences, with a commitment to improving patient outcomes, is required.
  • The ability to balance a high volume of patient and caregiver interactions and needs without compromising quality or responsiveness is required.
Responsibilities
  • Serve as the first point of contact for patients and caregivers by building trust, addressing inquiries, troubleshooting issues, and providing timely resolutions.
  • Guide new patients through the onboarding process, ensuring a seamless introduction to the device and application.
  • Proactively share patient and caregiver feedback with internal teams to inform product development, process improvements, and strategy.
  • Help maintain and update a knowledge base of technical support solutions, procedures, and documentation to assist and communicate with customers efficiently.
Desired Qualifications
  • Experience in the healthcare or pharmaceutical industry, with knowledge of regulatory requirements and compliance standards.
  • Experience with customer service software such as Zendesk or Salesforce.
  • Familiarity with digital therapeutics or medical devices.
  • Experience working in a startup or fast-paced environment, with the ability to adapt to change and navigate ambiguity.

MedRhythms develops neurotherapeutic solutions that aim to improve walking, mobility, and related brain health for people with neurologic injuries and diseases. Its core product is a proprietary platform that combines sensors, software, and music, guided by neuroscience, to target neural circuits and support functional recovery. The system works by delivering music-assisted therapy through sensor-driven feedback and software-based protocols that engage brain networks involved in movement, with services sold to healthcare providers and patients. What sets MedRhythms apart is its patented, integrated technology that merges music, sensors, and neuroscience into a single therapeutic approach, along with a multidisciplinary, nationwide team and a focus on translating neuroscience into practical mobility outcomes. The company’s goal is to improve life for individuals with movement disorders by restoring mobility and promoting brain health through accessible, clinician-supported therapies.

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$61.1M

Headquarters

Portland, Maine

Founded

2013

Get referred to MedRhythms

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Boston University won a January 27, 2026 grant to study MedRhythms' MOVIVE.
  • Edwards Health Care Services began national distribution on September 16, 2025.
  • CMS reimbursement and GSA/FSS access create a direct 2025-2026 commercial channel.

What critics are saying

  • A 2026 plan labels home RAS devices investigational, threatening payer adoption and sales.
  • Kalpaxis v. MedRhythms continues after the May 13, 2026 partial motion ruling.
  • The company depends on narrow stroke and Parkinson's reimbursement, risking existential slowdown if guidelines reject it.

What makes MedRhythms unique

  • MedRhythms pairs patented sensors, software, and music for home gait rehabilitation.
  • Movive gained FDA Class II listing on March 6, 2025, strengthening regulatory credibility.
  • InTandem earned CMS code E3200 and VA ordering access by April 2, 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Vacation

Paid Sick Leave

Parental Leave

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

5%

2 year growth

-1%
PR Newswire
Jul 7th, 2025
MedRhythms Appoints Larry Jasinski as Chief Executive Officer to Lead Next Phase of Growth and Commercial Expansion

PORTLAND, Maine, July 7, 2025 /PRNewswire/ - MedRhythms, Inc., a company pioneering the development of next-generation neurotherapeutics to improve walking, mobility and related functional outcomes, and creator of the world's first prescription music platform, announced the appointment of Larry Jasinski as Chief Executive Officer, effective immediately.

The Community Development Venture Capital Alliance
Apr 29th, 2025
CDVCA Invests in MedRhythms' Neurotherapy

CDVCA has made a follow-on investment in MedRhythms, a digital therapeutics company focused on improving mobility and quality of life for individuals with neurological conditions like strokes or multiple sclerosis. The investment supports MedRhythms' FDA-regulated prescription therapy technology and its commitment to advancing neurorehabilitation. Coastal Ventures 5, a CDVCA member fund, also participated in the investment.

PR Newswire
Apr 8th, 2025
Medrhythms Announces Availability Of Movive(Tm) For Parkinson'S Disease (Pd) For Veterans

PORTLAND, Maine, April 2, 2025 /PRNewswire/ -- MedRhythms today announced that Movive™, the company's neurorehabilitation system to support gait rehabilitation and motor function in adults with Parkinson's disease (PD), is now available for order within the U.S. Department of Veteran Affairs (VA) through the General Services Administration Multiple Award Schedule (GSA MAS), and also the Federal Supply Schedule (FSS)

University of Maine at Presque Isle
Apr 2nd, 2025
Libra Lecture Series presents Owen McCarthy

Under his leadership, MedRhythms has raised over $60 million in capital, was recognized as an FDA breakthrough technology, and created high-paying jobs - all while advancing cutting-edge technology that serves people nationwide.

PR Newswire
Mar 6th, 2025
Medrhythms Announces Fda Class Ii Listing For Movive™ To Support Gait Rehabilitation And Motor Function For Parkinson'S Disease

PORTLAND, Maine, March 6, 2025 /PRNewswire/ -- MedRhythms today announced that MR-005, the company's neurorehabilitation system to support gait rehabilitation and motor function in adults with Parkinson's disease (PD), has been listed as a Class II, Rx-only medical device with the U.S. Food and Drug Administration (FDA). The company unveiled the system's brand name: Movive™."Movive leverages the well-researched power of rhythmic auditory stimulation (RAS) for people with PD and is the second device to launch from MedRhythms' proprietary platform," said Brian Harris, Co-Founder and CEO of MedRhythms. "This is an exciting step for MedRhythms as we advance our mission to use music to address significant mobility challenges for people with neurologic injury and disease, including PD. We look forward to Movive's potential to support gait rehabilitation in PD, addressing a significant need."PD is the fastest growing neurodegenerative disease in the world. According to the Parkinson's Foundation , nearly one million Americans have PD, including 110,000 Veterans, making it the second most common neurodegenerative disease